Researchers led by Prof. HU Zheng from SIAT, uncovered a polyclonal origin of tumors, challenging the traditional clonal evolution theory. Using a DNA barcoding system in mouse models and genomic analysis of human colorectal samples, they demonstrated that colorectal precancers often arise from multiple distinct cellular lineages, which later transition to monoclonality as tumors progress. These findings, published in Nature, provide critical insights into the early evolution of colorectal cancer and offer new opportunities for preventing malignant transformation.

Researchers at the University of Toronto’s Faculty of Applied Science & Engineering have designed a new microfluidic platform that allows forunprecedented control and manipulation of tumor shapes — a largely unexplored area with great potential to advance cancer research.   

The work, led by Professor Edmond Young, offers new insights into how the shape of tumours can predict cancer cell behaviour and aggressiveness, which opens new pathways for more personalized and targeted cancer care.  

A $2.3 million National Cancer Institute grant will fund a University of Cincinnati Cancer Center study to develop a new technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.

BUFFALO, NY- November 15, 2024 – A new review was published in Volume 11 of Oncoscience on November 12, 2024, entitled, “Targeting carbohydrate metabolism in colorectal cancer - synergy between DNA-damaging agents, cannabinoids, and intermittent serum starvation.”

Recent research confirms that the gut microbiome plays a causal role in various chronic diseases, including infections, cancer, and inflammatory disorders, highlighting its potential as a therapeutic target. This review synthesizes evidence from randomized controlled trials, showing how microbiome therapies such as fecal microbiota transplantation (FMT) can reduce infection recurrence, improve immunotherapy response, and support remission in inflammatory conditions. The findings emphasize the microbiome’s promising role in future, non-invasive treatments for chronic disease management.